Destiny Pharma

Management Team

Bill Love, CEO

Destiny Pharma has developed a new class of anti-infective drug with outstanding, rapid, bactericidal activity against Staphylococcus aureus (SA), the world’s biggest cause of hospital bacterial infections. The lead drug, codenamed, XF-73 has completed a US government funded clinical trial.

Unlike traditional antibiotics, XF-73 has demonstrated in the lab the remarkable quality of withstanding SA bacterial resistance – yielding the potential for a range of low bacterial resistance medicines for the prevention and treatment of MRSA infections.

The need for new anti-infectives is urgent – recently, the 21st Century Cures Act has been passed by the US Congress to speed up the development and approval of such drugs. The FDA have awarded XF-73 Qualifying Infection Disease Status (QIDP) for the U.S. indication of 'Prevention of post-surgical Staphylococcal infection'. Which means that XF-73 will gain automatic Fast Track status when it is submitted for the next stage US clinical development.